Evidence map›Paper›PMID 37887379›Full record

ArticleMetabolites2023

Implications of Tioguanine Dosing in IBD Patients with a TPMT Deficiency.

Debbie S Deben, Luc J J Derijks, Bianca J C van den Bosch, Rob H Creemers, Annick van Nunen, Adriaan A van Bodegraven, Dennis R Wong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Metabolites, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Debbie S DebenDepartment of Clinical Pharmacy, Clinical Pharmacology and Toxicology, Zuyderland Medical Centre, 6162 BG Sittard, The Netherlands.ORCID 0000-0002-2956-5713
Luc J J DerijksDepartment of Clinical Pharmacy and Pharmacology, Máxima Medical Centre, 5504 DB Veldhoven, The Netherlands.
Bianca J C van den BoschDepartment of Clinical Genetics, Maastricht University Medical Centre (MUMC+), 6229 HX Maastricht, The Netherlands.
Rob H CreemersDepartment of Gastroenterology, Zuyderland Medical Centre, 6162 BG Sittard, The Netherlands.
Annick van NunenDepartment of Gastroenterology, Zuyderland Medical Centre, 6162 BG Sittard, The Netherlands.
Adriaan A van BodegravenDepartment of Gastroenterology, Zuyderland Medical Centre, 6162 BG Sittard, The Netherlands.ORCID 0000-0003-2636-303X
Dennis R WongDepartment of Clinical Pharmacy, Clinical Pharmacology and Toxicology, Zuyderland Medical Centre, 6162 BG Sittard, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tioguanine is metabolised by fewer enzymatic steps compared to azathioprine and mercaptopurine, without generating 6-methylmercaptopurine ribonucleotides. However, thiopurine S-methyl transferase (TPMT) plays a role in early toxicity in all thiopurines. We aimed to describe the hazards and opportunities of tioguanine use in inflammatory bowel disease (IBD) patients with aberrant TPMT metabolism and propose preventative measures to safely prescribe tioguanine in these patients. In this retrospective cohort study, all determined

Indexed as

inflammatory bowel disease (IBD)thiopurine S-methyl transferase (TPMT)tioguanineTPMT deficiency

Identifiers

PMID37887379
PMCPMC10608562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.